Skip to main content
. 2020 Jan 16;19(3):2431–2445. doi: 10.3892/ol.2020.11311

Figure 6.

Figure 6.

Prognostic efficacy of PTPRG-AS1 in GC evaluated using the Kaplan Meier Plotter. Kaplan-Meier survival curves revealed that poor OS of (A) all patients, (B) male patients, (C) female patients, (D) patients treated with surgery alone, (E) patients in clinical stage 3, (F) HER2 patients, (G) patients with no metastasis (M0), (H) patients with no lymph node metastasis (N0), and (I) patients with few lymph node metastasis sites (N1) was associated with high expression of PTPRG-AS1. PTPRG-AS1, PTPRG antisense RNA 1.